MiMedx Group, Inc. (NASDAQ:MDXG) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP increased its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 22.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 389,706 shares of the company's stock after purchasing an additional 72,432 shares during the period. Wellington Management Group LLP owned 0.26% of MiMedx Group worth $3,749,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of MDXG. IMG Wealth Management Inc. purchased a new position in shares of MiMedx Group during the fourth quarter worth about $28,000. Virtus Fund Advisers LLC acquired a new stake in shares of MiMedx Group in the 4th quarter valued at about $35,000. Van ECK Associates Corp purchased a new position in MiMedx Group during the 4th quarter worth approximately $40,000. Tower Research Capital LLC TRC grew its stake in MiMedx Group by 77.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after buying an additional 2,837 shares during the last quarter. Finally, AlphaQuest LLC acquired a new position in MiMedx Group during the fourth quarter worth approximately $88,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG traded up $0.15 during midday trading on Friday, reaching $6.49. 372,385 shares of the company were exchanged, compared to its average volume of 687,295. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The stock has a fifty day simple moving average of $6.85 and a 200 day simple moving average of $8.07. The stock has a market cap of $958.59 million, a P/E ratio of 11.80 and a beta of 1.82.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting analysts' consensus estimates of $0.06. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $88.21 million during the quarter, compared to analysts' expectations of $86.32 million. On average, research analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Transactions at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. The trade was a 1.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the transaction, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. This trade represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 141,907 shares of company stock worth $1,112,580 over the last 90 days. 1.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on MDXG shares. Wall Street Zen downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.